AdCOVID SARS-CoV-2 Vaccine Description
AdCOVID is a single dose intranasal vaccine candidate intending to prevent COVID-19 infections. AdCOVID has completed preclinical studies that were conducted with the University of Alabama at Birmingham.
AdCOVID is based on Altimmune Inc.'s adenovirus-based intranasal vaccine platform and expresses the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. The RBD is essential for viral infection and the majority of neutralizing antibodies from people that have recovered from COVID-19 bind to the RBD, highlighting the importance of the RBD in controlling the infection.
The AdCOVID vaccine is designed to offer significant advantages over other COVID-19 vaccine approaches, including intranasal administration, single-dose effectiveness, broad activation of the immune response, and the ability to ship and store the vaccine conveniently and inexpensively.
Because intranasal dosing can stimulate local mucosal immunity, AdCOVID is expected to guard the respiratory tract from viral invasion and provide downstream protection against the viral spread. Local mucosal immunity may be essential for creating sterilizing immunity that eliminates the last traces of viral infection in the nasal cavity.
In a non-peer-reviewed study published on October 11, 2020, the authors present data demonstrating strong activation of all (3) arms of the adaptive immune system following a single intranasal dose of AdCOVID. These data, conducted in (2) strains of mice, show that AdCOVID stimulated strong immune responses.
AdCOVID showed strong serum neutralizing activity and potent mucosal immunity in the respiratory tract. The induction of mucosal IgA antibodies in the respiratory tract may be necessary to block both infection and transmission of the virus to prevent further spread of COVID-19.
On November 10, 2020, Dr. Vipin K. Garg, President, and CEO of Altimmune, said in a press release, “We strongly believe there is a compelling need for next-generation COVID-19 vaccines and are rapidly advancing our development program for AdCOVID to meet this demand. We plan to commence a clinical study of AdCOVID in the fourth quarter, with a data readout from this study anticipated in the first quarter of 2021.”
Maryland based Altimmune is a clinical-stage biopharmaceutical company focused on developing intranasal vaccines, immune-modulating therapies, and treatments for liver disease. The company's platform vaccines (NasoVAX and NasoShield) have shown an excellent stability profile and, when combined with the simple intranasal route of administration, may allow for efficient and inexpensive distribution of the vaccine.
AdCOVID SARS-CoV-2 Vaccine Indication
The AdCOVID vaccine candidate is indicated to prevent infection as well as transmission of COVID-19. Because intranasal dosing can stimulate local mucosal immunity, AdCOVID is expected to guard the respiratory tract from viral invasion and provide downstream protection against the viral spread. Local mucosal immunity may be essential for creating sterilizing immunity that eliminates the last traces of viral infection in the nasal cavity.
AdCOVID also provides an easier route of administration than an injection eliminating the need for administration by trained medical personnel and may even allow for self-administration.
Pediatric and pregnancy efficacy verification remains TBD.
AdCOVID SARS-CoV-2 Vaccine News
November 25, 2020 - Altimmune, Inc. announced that it has submitted an Investigational New Drug application to the U.S. FDA to commence a Phase 1 clinical study of its single-dose intranasal COVID-19 vaccine candidate, AdCOVID.
November 10, 2020 - Altimmune, Inc. announced that it entered into an agreement with Lonza for the manufacturing of AdCOVID™, Altimmune’s next-generation, a single-dose intranasal vaccine candidate for COVID-19. Lonza is a leading global biopharmaceutical manufacturing company with facilities in Europe, North America, and South Asia.
October 12, 2020 - Altimmune Inc. announced a preclinical evaluation of its single-dose, intranasal vaccine candidate, AdCOVID. The pre-clinical studies were conducted as part of Altimmune’s ongoing collaboration with the University of Alabama at Birmingham. These researchers stated 'AdCOVID, which promotes concomitant systemic and local mucosal immunity, represents a promising COVID-19 vaccine candidate.'
September 28, 2020 - Altimmune, Inc. announced that Scot Roberts, Ph.D., Chief Scientific Officer, presented an overview of the Company’s AdCOVID and T-COVID intranasal vaccine and therapeutic candidates at the World Vaccine Congress Washington.
March 30, 2020 - Altimmune, Inc. announced that it is launching a collaboration with the University of Alabama at Birmingham (UAB) on the development of its single-dose, intranasal COVID-19 vaccine, named AdCOVID.
AdCOVID SARS-CoV-2 Vaccine Clinical Trials
Based on the positive outcomes of the preclinical study, the Company plans to advance the vaccine candidate to a Phase 1 safety and immunogenicity study in Q4 of 2020.